#Europe

Another initiative of the Elton John AIDS Foundation will focus on HIV and hep C in Eastern Europe and Central Asia.

The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.

This is the first decline in the rate since the mid-1990s, with a major London sexual health clinic charting an 80 percent drop since 2015.

The news first broke in February about a man in Amsterdam who contracted non-drug-resistant HIV while apparently adhering well to PrEP.

HIV scientists and advocates are waging a powerful war against the global epidemic.

Researchers advocate for laws protecting both populations as a way to slow HIV transmission among male immigrants who have sex with men.

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

Treating more of this population with antiretrovirals and improving screening could accelerate the decline.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

A Dutch study that offered men Truvada as prevention under either dosing protocol helps shed light on that question.

An analysis of the “on-demand” PrEP study found no new HIV infections among those reporting good adherence and relatively infrequent sex.

In a British study, men on PrEP also reported many psychosocial benefits to using Truvada for prevention.

For the first time, more than half of people with HIV are taking meds. The analysis also shows troubling trends in the former Soviet region.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Men who have sex with men traveling to the region are advised to get vaccinated for hepatitis A virus.

The HIV population in Western and Southern Europe is nearing the United Nations’ “90-90-90” goals for tackling the epidemic.